Subscribe to RSS
DOI: 10.1055/s-0044-1781438
Optimal Screening for Hereditary Head and Neck Paraganglioma in Asymptomatic SDHx Variant Carriers in the Netherlands
Abstract
Background SDHx variant carriers have an increased risk of developing head and neck paraganglioma. The Dutch guidelines state that these patients require lifelong follow-up, but no clear recommendation is made about the frequency of screening.
Objective To determine the annual risk of developing head and neck paraganglioma in SDHx variant carriers after a negative initial screening.
Methods We conducted a retrospective single-center cohort study in the Netherlands that included 49 SDHA, SDHB, and SDHD variant carriers with a negative first screening and at least one follow-up. The main outcome measure was the annual risk of developing a paraganglioma for the SDHx variants separately.
Results Between 2000 and 2022, nine patients developed a paraganglioma all of whom were carriers of a SDHD variant (n = 23). Neither the 24 SDHB-related cases nor the 2 SDHA variant carriers developed a paraganglioma after a median of 4.83 and 5.92 years of follow-up, respectively.
Conclusion The 5-year risk for head and neck paragangliomas in pathological SDHx variant carriers is less than 20%. A 5-year interval for screening SDHx carriers seems sufficient to prevent the unnoticed development of head and neck paragangliomas that warrant treatment.
Publication History
Received: 23 November 2023
Accepted: 23 January 2024
Article published online:
01 March 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Williams MD. Paragangliomas of the head and neck: an overview from diagnosis to genetics. Head Neck Pathol 2017; 11 (03) 278-287
- 2 Arts HA, Fagan PA. Vagal body tumors. Otolaryngol Head Neck Surg 1991; 105 (01) 78-85
- 3 Young Jr WF. Paragangliomas: clinical overview. Ann N Y Acad Sci 2006; 1073: 21-29
- 4 Cass ND, Schopper MA, Lubin JA, Fishbein L, Gubbels SP. The changing paradigm of head and neck paragangliomas: what every otolaryngologist needs to know. Ann Otol Rhinol Laryngol 2020; 129 (11) 1135-1143
- 5 Boedeker CC, Ridder GJ, Schipper J. Paragangliomas of the head and neck: diagnosis and treatment. Fam Cancer 2005; 4 (01) 55-59
- 6 Hensen EF, Siemers MD, Jansen JC. et al. Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients. Clin Endocrinol (Oxf) 2011; 75 (05) 650-655
- 7 Kunst HP, Rutten MH, de Mönnink JP. et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res 2011; 17 (02) 247-254
- 8 Benn DE, Gimenez-Roqueplo AP, Reilly JR. et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006; 91 (03) 827-836
- 9 Neumann HP, Pawlu C, Peczkowska M. et al; European-American Paraganglioma Study Group. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292 (08) 943-951
- 10 van der Tuin K, Mensenkamp AR, Tops CMJ. et al. Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: a nationwide study. J Clin Endocrinol Metab 2018; 103 (02) 438-445
- 11 Nederlandse Vereniging voor Keel-Neus-Oorheelkunde (NVKNO), Hoofd-/halsparagangliomen (HHPGL). 2012 [08-03-2022]; Available from: https://richtlijnendatabase.nl/richtlijn/hoofd-_halsparagangliomen_hhpgl/behandeling_hoofd-_halsparagangliomen/wait-en-scan_beleid_bij_hhpgl.html
- 12 Heesterman BL, Bayley JP, Tops CM. et al. High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Eur J Hum Genet 2013; 21 (04) 469-470
- 13 Saie C, Buffet A, Abeillon J. et al. Screening of a large cohort of asymptomatic SDHx mutation carriers in routine practice. J Clin Endocrinol Metab 2021; 106 (03) e1301-e1315
- 14 Tufton N, Sahdev A, Akker SA. Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers. J Endocr Soc 2017; 1 (07) 897-907
- 15 Amar L, Pacak K, Steichen O. et al. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol 2021; 17 (07) 435-444
- 16 Rijken JA, Niemeijer ND, Jonker MA. et al. The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers. Clin Genet 2018; 93 (01) 60-66
- 17 Hensen EF, Jansen JC, Siemers MD. et al. The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. Eur J Hum Genet 2010; 18 (01) 62-66
- 18 Heesterman BL, de Pont LMH, Verbist BM. et al. Age and tumor volume predict growth of carotid and vagal body paragangliomas. J Neurol Surg B Skull Base 2017; 78 (06) 497-505